信立泰(002294.SZ):擬將“重組人促卵泡激素-CTP融合蛋白注射液”中國大陸地區的全部技術所有權和知識產權轉讓給金賽藥業
格隆匯 12 月 11日丨信立泰(002294.SZ)公佈,為聚焦核心戰略領域,專注創新研發,提高資產運營效率,公司全資子公司信立泰(成都)生物技術有限公司(“成都信立泰”)擬與長春金賽藥業有限責任公司(“金賽藥業”)簽訂協議,將成都信立泰所有的處於I期臨牀試驗階段的在研品種“重組人促卵泡激素-CTP融合蛋白注射液”中國大陸地區的全部技術所有權和知識產權(包括與製造該重組人促卵泡激素-CTP融合蛋白注射液有關的實體物品,以及相關知識產權、非專利技術等研發成果的所有權,以及由標的轉讓產生的後續全部權利和經濟收益)轉讓給金賽藥業。公司將根據協議進展情況,按里程碑獲得總金額為人民幣6068萬元的技術轉讓費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.